ANDA 88200, held by Sandoz. Hydrochlorothiazide; Reserpine.
As of Nov 16, 2026, ANDA 88200 (Reserpine And Hydrochlorothiazide), held by Sandoz, was not approved, with 1 approved supplement and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Reserpine And Hydrochlorothiazide50MG;0.125MG ยท tablet;oral | Hydrochlorothiazide; Reserpine | Discontinued |
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 1, 1984 | Supplement 1Manufacturing | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters